Disease · MONDO_0002046

alcohol abuse

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. alcohol abuse. Diseases, record MONDO_0002046. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002046

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: alcohol abuse; Open Targets
Open Targets ID: MONDO_0002046; Open Targets
Disease Ontology: DOID:1574; Disease Ontology
MeSH: D000437; MeSH
Highest stage of its drugs: Phase 2, for 2 of its 5 drugs, from ClinicalTrials.gov; Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
MEMANTINE	CHEMBL807	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
SERTRALINE	CHEMBL809	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IBUDILAST	CHEMBL19449	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
LEFELSIRAN	CHEMBL5314647	Oligonucleotide	Unknown	USAN	1	0	0	Drugs and targets
LEFELSIRAN SODIUM	CHEMBL5314646	Oligonucleotide	Unknown	USAN	1	0	0	Drugs and targets

Targets15

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GRIN1	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2902	Drugs and targets
GRIN2A	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2903	Drugs and targets
GRIN2B	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2904	Drugs and targets
GRIN2C	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2905	Drugs and targets
GRIN2D	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/2906	Drugs and targets
GRIN3A	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/116443	Drugs and targets
GRIN3B	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 2	https://conductscience.org/library/genes/116444	Drugs and targets
PDE10A	cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	1	Phosphodiesterase 10A inhibitor	Phase 1	https://conductscience.org/library/genes/10846	Drugs and targets
PDE3A	cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A	1	Phosphodiesterase 3A inhibitor	Phase 1	https://conductscience.org/library/genes/5139	Drugs and targets
PDE4A	Phosphodiesterase 4	1	Phosphodiesterase 4 inhibitor	Phase 1	https://conductscience.org/library/genes/5141	Drugs and targets

1 to 10 of 15

See all 15 targets

Trials3

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01585168	Functional Neuroimaging of Alcoholism Vulnerability (PIT)	Phase 2	71	2018-05-25	Healthy	MEMANTINE	Its record names the disease	ClinicalTrials.gov
NCT02025998	Development of Ibudilast for Alcohol Use Disorder	Phase 1	24		Alcohol Use Disorders	IBUDILAST	Its record names the disease	ClinicalTrials.gov
NCT00249431	Effectiveness of Sertraline in Treating Pathological Gamblers With a Diagnosis of Alcohol Dependence - 1	Phase 2	9		Alcoholism, Gambling	SERTRALINE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials2

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Family History Positive (FHP) vs Family History Negative (FHN): deaths from any cause	0 of 35	0 of 36	71	NCT01585168	Trial comparisons
Family History Positive (FHP) vs Family History Negative (FHN): serious adverse events	0 of 35	0 of 36	71	NCT01585168	Trial comparisons

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
36130734	DERIVED	1	PubMed
36102596	DERIVED	1	PubMed
29794557	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002046

GET https://conductscience.org/api/diseases/v1/MONDO_0002046/drugs

API reference For AI assistants